Jenburkt Pharmaceuticals Ltd. Quarterly Results: Standalone & Consolidated Reports

Quarterly Results

Results Snapshot

YoYQoQ

Figures in Cr

Standalone Quarterly Results

Dec'25

Sep'25

Jun'25

Mar'25

Dec'24

Sep'24

Jun'24

Quarterly Analysis Highlights - QoQ

Net Sales

QoQ Growth in quarter ended Dec 2025 is -5.58% vs 28.23% in Sep 2025

Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is -41.63% vs 30.42% in Sep 2025

Operating Profit (PBDIT) excl Other Income

QoQ Growth in quarter ended Dec 2025 is -43.36% vs 46.21% in Sep 2025

Interest

QoQ Growth in quarter ended Dec 2025 is 9.09% vs 0.00% in Sep 2025

Operating Profit Margin (Excl OI)

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

Compare Quarterly Results Of Jenburkt Pharma With

Select Peers

Figures in Cr

Standalone Quarterly Results

Change(INR)

Change(%)

Net Sales

43.02

42.23

0.79

1.87%

Other Operating Income

0.00

Total Operating income

43.02

42.23

0.79

1.87%

Raw Material Cost

2.47

21.26

-18.79

-88.38%

Purchase of Finished goods

7.83

0.00

7.83

(Increase) / Decrease In Stocks

-1.51

1.18

-2.69

-227.97%

Employee Cost

14.71

5.71

9.00

157.62%

Power Cost

0.00

Manufacturing Expenses

0.00

Selling and Distribution Expenses

0.00

Other Expenses

12.10

9.06

3.04

33.55%

Total Expenditure (Excl Depreciation)

35.60

37.21

-1.61

-4.33%

Operating Profit (PBDIT) excl Other Income

7.42

5.02

2.40

47.81%

Other Income

1.82

0.37

1.45

391.89%

Operating Profit (PBDIT)

9.24

5.39

3.85

71.43%

Interest

0.12

0.81

-0.69

-85.19%

Exceptional Items

0.00

Gross Profit (PBDT)

9.12

4.58

4.54

99.13%

Depreciation

0.83

1.81

-0.98

-54.14%

Profit Before Tax

8.30

2.77

5.53

199.64%

Tax

2.37

0.56

1.81

323.21%

Provisions and contingencies

0.00

Profit After Tax

5.93

2.21

3.72

168.33%

Extraordinary Items

0.00

Prior Period Expenses

0.00

Other Adjustments

0.00

Net Profit

5.93

2.21

3.72

168.33%

Equity Capital

4.41

13.56

-9.15

-67.48%

Face Value

10.00

0.00

Reserves

0.00

Earnings per share (EPS)

13.45

1.63

11.82

725.15%

Diluted Earnings per share

13.44

1.63

11.81

724.54%

Operating Profit Margin (Excl OI)

17.25%

11.89%

0.00

5.36%

Gross Profit Margin

21.20%

10.85%

0.00

10.35%

PAT Margin

13.78%

5.23%

0.00

8.55%

Public Share Holdings (%)

0.00%

0.00

0.00%

Pledged Promotor Holding (%)

0.00%

0.00

0.00%

Quarterly - Net Sales

Net Sales 43.02 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is -5.58% vs 28.23% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 16.62% vs 3.45% in Dec 2024

Quarterly - Standalone Net Profit

Standalone Net Profit 5.93 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is -41.63% vs 30.42% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -8.91% vs 20.56% in Dec 2024

Quarterly - Operating Profit (PBDIT)

Operating Profit (PBDIT) 7.42 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is -43.36% vs 46.21% in Sep 2025

YoY Growth in quarter ended Dec 2025 is -15.87% vs 22.50% in Dec 2024

Quarterly - Interest

Interest 0.12 Cr

in Dec 2025

Figures in Cr

QoQ Growth in quarter ended Dec 2025 is 9.09% vs 0.00% in Sep 2025

YoY Growth in quarter ended Dec 2025 is 9.09% vs 57.14% in Dec 2024

Quarterly - Operating Profit Margin (Excl OI)

Operating Profit Margin (Excl OI) 17.25%

in Dec 2025

Figures in %

QoQ Growth in quarter ended Dec 2025 has fallen from Sep 2025

YoY Growth in quarter ended Dec 2025 has fallen from Dec 2024